8[3]Lubrano C,sciarra F,spera G,et al.Immunoreactive EGF in human benign prostatic hyperplasia:relationships with and estrogen receptors. J steroid Biochem Mol Biol,1992,41:683～687
9[4]Nakano K,Fukabori Y,Itoh N,et al.Androgen stimu last human prostate epithelial growth mediated by stroml-fibrobkast growth factor 10. Endocr J, 1999,4: 405～413
4Khastgir J, Arya M. Current concepts in the pharmacothapy of benign prostatic hyperplasia[J]. Expert opin pharmacother, 2002, 3(12): 1727-1737.
5Anderson K E. Storage and voiding symptoms: pathophysiologic acpects [J]. Urology, 2003, 62(5 Suppl2): 3-10.
6Spigt M G, Van K P, et al. Pathophysiological aspects of bladder dysfunction: a new hypothesis tbr the prevention of prostatic symptoms [J]. MedHypoththeses, 2004, 62(3): 448-452.
7Zhong-jian CHEN, Kenneth P MINNEMAN. Recent progress in otl-adrenergic receptor research. Acta Pharmac-ologica Sinica[J]. 2005, 26(11 ): 1281-1287.
8Helfand BT, Evans RM, McVary KT. A comparison of the frequencies of medical therapies for overactive bladder in men and women, analysis of more 7.2 million aging patiens. EurUrol, 2010, 57: 586-591.
9Athanasopoulos A, Gyffopoulos K, et al. Combination treatment with ,an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prosperctive, randomized, controlled study. Urology, 2003, 169(60): 2253-2256.
10Mohammad-Ali Haghshenol, Dan Mellstrrm, et al. Lower urinary tract symptoms are associated with low levels of serum serotonin, high levels of adiponectin and fasting glucose, and benign prostatic enlargement. Scandinavian JournalofUrology[J]. 2014: 1-7.
